1. Disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis: effectiveness and value : final evidence report Publication: Boston, MA : Institute for Clinical and Economic Review, March 6, 2017 Subject(s): Comparative Effectiveness ResearchMultiple Sclerosis, Chronic Progressive -- drug therapyMultiple Sclerosis, Relapsing-Remitting -- drug therapyAntirheumatic Agents -- adverse effectsAntirheumatic Agents -- economicsAntirheumatic Agents -- therapeutic useBenchmarkingCost-Benefit AnalysisImmunosuppressive Agents -- adverse effectsImmunosuppressive Agents -- economicsImmunosuppressive Agents -- therapeutic useInsurance CoverageRandomized Controlled Trials as TopicTreatment OutcomeHumansUnited States
